The yeast Saccharomyces cerevisiae has been useful in establishing the phenotypic effects of specific mutations on the enzymatic activity and camptothecin sensitivity of yeast and human DNA topoisomerase I. To determine whether these phenotypes were faithfully reiterated in higher eukaryotic cells, wild-type and mutant yeast Top1 proteins were epitope-tagged at the amino terminus and transiently overexpressed in mammalian COS cells. Camptothecin preferentially induced apoptosis in cells expressing wild-type eScTop1p yet did not appreciably increase the cytotoxic response of cells expressing a catalytically inactive (eSctop1Y727F) or a catalytically active, camptothecin-resistant eSctop1vac mutant. Using an epitope-specific antibody, immobilized precipitates of eScTop1p were active in DNA relaxation assays, whereas immunoprecipitates of eScTop1Y727Fp were not. Thus, the enzyme retained catalytic activity while tethered to a support. Interestingly, the mutant eSctop1T722A, which mimics camptothecin-induced cytotoxicity in yeast through stabiliza- Eukaryotic DNA topoisomerase I catalyzes the relaxation of supercoiled DNA through the transient breakage and religation of a single DNA strand in a DNA duplex (reviewed in Refs. 1-3). This enzyme plays a role in a number of essential cellular processes, such as replication, recombination, and transcription (1, 3-5). Furthermore, the naturally occurring antitumor drug camptothecin specifically targets this enzyme by stabilizing the covalent enzyme-DNA intermediate (Refs. 6 and 7; reviewed in Ref. 8). During DNA replication (S phase), these stabilized enzyme-DNA adducts are converted into lethal double-stranded DNA breaks due to their interaction with the DNA replication fork (9 -12).Although this enzyme participates in numerous cellular processes, strains of the yeast Saccharomyces cerevisiae deleted for the gene encoding DNA topoisomerase I (top1⌬) are viable because other gene products, such as DNA topoisomerase II, can compensate for the loss of TOP1 (11, 13). These top1⌬ strains are completely resistant to the cytotoxic action of camptothecin (14 -16). However, expression of either S. cerevisiae or human DNA topoisomerase I restores the sensitivity of these cells to camptothecin-induced lethality (4, 14 -16). These results demonstrate the specificity of camptothecin for eukaryotic DNA topoisomerase I and the utility of using yeast as a model system for the analysis of drug-enzyme interactions. In fact, mutations in yeast and human TOP1 that render the enzyme resistant to camptothecin (17,18) or render the enzyme cytotoxic even in the absence of camptothecin (19, 20) 1,2 have been defined using this yeast system.These results indicate a significant conservation of function between the yeast and human enzymes, consistent with extensive similarities in TOP1 sequences. Nevertheless, differences between these proteins do exist. For example, expression of a camptothecin-resistant yeast or human DNA topoisomerase I mutant (top1vac) has different effects on the viability of ...